1011 On Other Exchanges
1011 is not on other exchanges.

china nt pharma group co ltd (1011) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHINA NT PHARMA GROUP CO LTD (1011)

Related News

No related news articles were found.

china nt pharma group co ltd (1011) Related Businessweek News

No Related Businessweek News Found

china nt pharma group co ltd (1011) Details

China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical and vaccine products in the People’s Republic of China. It operates through three segments: Third-Party Pharmaceutical Promotion and Sales; Proprietary Products Production and Sales; and Third-Party Vaccines and Other Pharmaceuticals. The Third-Party Pharmaceutical Promotion and Sales segment engages in selling and marketing third-party manufactured pharmaceutical products to customers, as well as providing marketing and promotion services. The Proprietary Products Production and Sales segment is involved in the production and sale of NT branded products and generic drugs. The Third-Party Vaccines and Other Pharmaceuticals segment provides supply chain services for pharmaceutical/vaccine products. The company is also involved in the trading of prescription medicines; and provision of logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Shanghai, the People's Republic of China.

432 Employees
Last Reported Date: 09/23/16
Founded in 1995

china nt pharma group co ltd (1011) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: CNY6.5M
Executive Director
Total Annual Compensation: --
Vice President, Executive Director and Chairm...
Total Annual Compensation: CNY942.0K
Compensation as of Fiscal Year 2015.
china nt pharma group co ltd
China NT Pharma Group Company Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

China NT Pharma Group Company Limited reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported revenue of RMB 385,789,000 compared with RMB 380,903,000 for the same period last year. Profit from operations was RMB 62,048,000 compared with RMB 57,181,000 for the same period last year. Profit before taxation was RMB 54,034,000 compared with RMB 38,161,000 for the same period last year. Profit attributable to equity shareholders of the company was RMB 50,068,000 or 3.16 cents diluted per share compared with RMB 36,490,000 or 2.84 cents basic and diluted per share for the same period last year. The decrease in revenue from third-party pharmaceutical promotion and sales was primarily due to a decrease in sales of Fortum, an antibiotic manufactured by GlaxoSmithKline Plc. The Group ceased to be the promotor and distributor of Fortum since 1 July 2015. Core profit attributable to equity holders of the company was RMB 51.3 million as compared to a core profit of RMB 48.0 million for the period ended 30 June 2015, which was mainly attributable to the reduction in operating expenses and decrease in finance costs. Diluted core earnings per share was 3.24 cents compared to 3.73 cents a year ago. Total capital expenditure increased by RMB 2.9 million or 20.8% to RMB 16.7 million for the period ended 30 June 2016, as compared to RMB13.8 million for the period ended 30 June 2015. The capital expenditure was mainly used for acquiring the leasehold land, fixed assets and intangible assets of the Group's new factory in Changsha.

China NT Pharma Seeks Acquisitions

China NT Pharma Group Company Limited (SEHK:1011) (‘NT Pharma’) is looking for acquisitions. Ng Tit, Chairman and Chief Executive Officer of NT Pharma, said that the Group will continue to actively identify opportunities to acquire new proprietary products and strive to create more value for shareholders and patients.

China NT Pharma Group Company Limited to Report First Half, 2016 Results on Aug 18, 2016

China NT Pharma Group Company Limited announced that they will report first half, 2016 results on Aug 18, 2016


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1011 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1011.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1011 Industry Range
Price/Earnings 21.1x
Price/Sales 2.5x
Price/Book 2.3x
Price/Cash Flow 20.8x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA NT PHARMA GROUP CO LTD, please visit www.ntpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.